407601
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor
The Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor controls the activity of Interleukin-1 Receptor-Associated-Kinase-1/4. Primarily used for Phosphorylation & Dephosphorylation apps.
别名:
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor, IRAK-1/4 Inhibitor, N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
crystalline solid
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
yellow
溶解度
DMSO: 10 mg/mL
運輸包裝
ambient
儲存溫度
−20°C
InChI
1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
InChI 密鑰
QTCFYQHZJIIHBS-UHFFFAOYSA-N
一般說明
A cell-permeable benzimidazole compound that acts as a potent and selective inhibitor of interleukin-1 receptor-associated kinases (IC50 = 300 nM and 200 nM for IRAK-1 and -4). Shown to exhibit little activity against a panel of 27 other kinases (IC50 >10 µM), including lck and src.
A cell-permeable benzimidazole compound that acts as a potent and selective inhibitor of interleukin-1 receptor-associated kinases (IC50 = 300 nM and 200 nM for IRAK-1 and -4). Shown to exhibit little activity against a panel of 27 other kinases (IC50 >10 µM), including lck and src. Also available as a 25 mM solution in DMSO (Cat. No. 407602).
生化/生理作用
Cell permeable: yes
Primary Target
Interleukin-1 receptor-associated kinases
Interleukin-1 receptor-associated kinases
Product does not compete with ATP.
Reversible: no
Target IC50: 300 nM and 200 nM for IRAK-1 and -4
包裝
Packaged under inert gas
警告
Toxicity: Harmful (C)
其他說明
Bhattacharyya, S., et al. 2007. Am. J. Physiol. Gastrointest. Liver Physiol.293, G429.
Powers, J.P., et al. 2006. Bioorg. Med. Chem. Lett.16, 2842.
Powers, J.P., et al. 2006. Bioorg. Med. Chem. Lett.16, 2842.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
The New England journal of medicine, 367(9), 826-833 (2012-08-31)
Waldenström's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic lymphoma (LPL). The underlying mutation in this disorder has not been delineated. We performed whole-genome sequencing of bone marrow LPL cells in 30 patients with Waldenström's macroglobulinemia, with paired normal-tissue and tumor-tissue sequencing
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门